Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond

SIMPLE SUMMARY: Although immunotherapy has revolutionized the standard of care of many cancers, its efficacy in soft tissue sarcomas has been disappointing so far. Nevertheless, some recent studies have reported meaningful activity in a few selected histotypes, especially alveolar soft part sarcoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Fazel, Mina, Dufresne, Armelle, Vanacker, Hélène, Waissi, Waisse, Blay, Jean-Yves, Brahmi, Mehdi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046205/
https://www.ncbi.nlm.nih.gov/pubmed/36980528
http://dx.doi.org/10.3390/cancers15061643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046205/
https://www.ncbi.nlm.nih.gov/pubmed/36980528
http://dx.doi.org/10.3390/cancers15061643

Ejemplares similares